 | Up a level |
Ataseven, B., Rhiem, K., Staniczok, C., Heitz, F., Pauly, N., Moubarak, M., Concin, N., Traut, A., Schmutzler, R. and Harter, P. (2022). Prevalence and oncological outcome of patients with primary epithelial ovarian cancer (EOC) carrying gene mutations or variants of unknown signifikance (VUS) detected by germline gene panel testing. Geburtshilfe Frauenheilkd., 82 (10). S. E44 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Ataseven, B., Tripon, D., Schwameis, R., Harter, P., Rhiem, K., Schneider, S., Heikaus, S., Baert, T., Alesina, P., Heitz, F., Traut, A., Groeben, H. T., Schmutzler, R. and du Bois, A. (2021). Impact of BRCA1/2 Germline Status on intraperitoneal Tumor Distribution, Operability, and Incidence of postoperative Complications in Patients with epithelial Ovarian Cancer. Geburtshilfe Frauenheilkd., 81 (4). S. E2 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Berling-Ernst, A., Yahiaoui-Doktor, M., Kiechle, M., Engel, C., Lammert, J., Grill, S., Dukatz, R., Rhiem, K., Baumann, F. T., Bischoff, S. C., Erickson, N., Schmidt, T., Niederberger, U., Siniatchkin, M. and Halle, M. (2022). Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1). Sci Rep, 12 (1). BERLIN: NATURE PORTFOLIO. ISSN 2045-2322
Buelow, L., Keupp, K., Richters, L., Pohl, E., Wappenschmidt, B., Zarghooni, V., Reichstein-Gnielinski, S., Maringa, M., Giesecke, J., Rhiem, K., Hahnen, E. and Schmutzler, R. (2017). Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Danner, M., Mueller, D., Schmutzler, R., Rhiem, K., Engel, C., Stollenwerk, B., Stock, S. and Wassermann, K. (2016). ECONOMIC MODELING OF RISK-ADAPTED SCREEN-AND-TREAT STRATEGIES IN WOMEN AT HIGH-RISK FOR BREAST OR OVARIAN CANCER. Value Health, 19 (7). S. A737 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1524-4733
Dick, J., Rhiem, K., Bredart, A., Stock, Stephanie 
ORCID: 0000-0002-1726-9300 and Schmutzler, Rita K. ORCID: 0000-0001-8160-4348
(2018).
An international multicenter cross-sectional prospective study in improving psychosocial care for women with breast cancer risk after diagnostic gene sequencing (BRIDGES).
Oncology research and treatment, 41.
S. 35 - 37.
BASEL:
KARGER.
ISSN 2296-5262
Dick, J., Rhiem, K., Herold, N., Huebbel, A., Huebbel, V., Bredow, K., Giesecke, J., Reichstein-Gnielinski, S., Maringa, M., Scheer, N. and Schmutzler, R. K. (2018). Influence factors on the preference for preventive strategies in healthy BRCA1/2 Mutation carriers. Oncol. Res. Treat., 41. S. 37 - 38. BASEL: KARGER. ISSN 2296-5262
Dick, J., Rhiem, K., Mensah, J., Wesselmann, S. and Schmutzle, R. K. (2018). Survey on physicians' training needs in counselling of persons with familial breast and ovarian cancer risk. Oncol. Res. Treat., 41. S. 36 - 37. BASEL: KARGER. ISSN 2296-5262
Dukatz, R., Halle, M., Engel, C., Berling, A., Hebestreit, K., Bischoff, S., Pfeifer, K., Grill, S., Yahiaoui-Doktor, M., Enders, U., Siniatchkin, M., Gerber, D., Bridstrup, J., Erickson, N., Loeffler, M., Meindl, A., Rhiem, K., Schmutzler, R. and Kiechle, M. (2016). Feasibility assessment on a lifestyle intervention in healthy and diseased BRCA 1/2 mutation carriers. Oncol. Res. Treat., 39. S. 59 - 60. BASEL: KARGER. ISSN 2296-5262
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U and Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol., 32 (1). S. 49 - 58. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Pohl-Rescigno, E., Portnicki, M., Rhiem, K. and Schmutzler, R. (2020). Implementation of an educational program and risk-adjusted prevention program for breast and ovarian cancer of the German Consortium for Hereditary Breast- and Ovarian Cancer. Geburtshilfe Frauenheilkd., 80 (6). S. E37 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Herold, N., Bredow, K., Hahnen, E., Wappenschmidt, B., Hauke, J., Wiedemann, R., Waha, A., Bluemcke, B., Portnicki, M., Pohl-Rescigno, E., Rhiem, K., Kast, K., Huebbel, V, Maringa, M., Crombach, G. and Schmutzler, R. (2020). Knowledge-generating Care using the Example of hereditary Breast- and Ovarian Cancer (BC/OC): Evaluation of the comprehensive Care Concept. Geburtshilfe Frauenheilkd., 80 (10). S. E212 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Herold, N., Lichenheldt, F., Hillebrand, V., Wappenschmidt, B., Hahnen, E., Rhiem, K. and Schmutzler, R. K. (2018). Evaluation of prophylactic mastectomy and breast reconstruction in female BRCA1/2 mutation carriers. Oncol. Res. Treat., 41. S. 41 - 42. BASEL: KARGER. ISSN 2296-5262
Holly, J., Harter, P., Ataseven, B., Moubarak, M., Schwameis, R., Heikaus, S., Concin, N., Rhiem, K., Denkert, C. and Heitz, F. (2022). HRD Testing and BRCA1/2 Germline Testing in routine clinical Practice in Female Patients with primary Ovarian Cancer. Geburtshilfe Frauenheilkd., 82 (4). S. E5 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Imterat, M., du Bois, A., Harter, P., Rhiem, K., Heitz, F., Concin, N., Traut, A., Schmutzler, R. and Ataseven, B. (2022). Incidence and prognostic impact of pathogenic germline mutations in gene panel testing of primary advanced epithelial ovarian cancer patients. Geburtshilfe Frauenheilkd., 82 (10). S. E97 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Isselhard, A., Toepper, M., Berger-Hoeger, B., Steckelberg, A., Fischer, H., Vitinius, F., Beifus, K., Koeberlein-Neu, J., Wiedemann, R., Rhiem, K., Schmutzler, R. and Stock, S. (2020). Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study. Trials, 21 (1). LONDON: BMC. ISSN 1745-6215
Keupp, K., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Larsen, M., Buelow, L., Kroeber, S., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2018). Next-generation sequencing via TruRisk (R) genepanel reveal high mutation prevalence in additional risk genes in German BRCA1/2-negative breast and ovarian cancer families. Eur. J. Hum. Genet., 26. S. 541 - 543. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5438
Keupp, K., Richters, L., Buelow, L., Kroeber, S., Ernst, C., Bluemcke, B., Versmold, B., Waha, A., Driesen, J., Baasner, A., Altmueller, J., Thiele, H., Nuernberg, P., Wappenschmidt, B., Neidhardt, G., Rhiem, K., Schmutzler, R., Hahnen, E. and Hauke, J. (2017). TruRisk (R) based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., Furlanetto, J., Zahm, D. M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P. A., Nekljudova, V., Denkert, C. and Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann. Oncol., 33 (11). S. 1149 - 1159. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J. -U., Grischke, E. -M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2022). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study (vol 30, pg 1279, 2019). Ann. Oncol., 33 (7). S. 743 - 745. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B., V, Blohmer, J-U, Grischke, E-M, Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol., 30 (8). S. 1279 - 1289. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Neidhardt, G., Hauke, J., Heilmann, S., Hellebrand, H., Surowy, H. M., Klaschik, K., Honisch, E., Gehrig, A., Sutter, C., Rump, A., Bogdanova-Markov, N., Bugert, P., Mangold, E., Steinemann, D., Ramirez, A., Ditsch, N., Arnold, N., Niederacher, D., Burwinkel, B., Thiele, H., Altmueller, I., Nuernberg, P., Engel, C., Wappenschmidt, B., Rhiem, K., Meindl, A., Schmutzler, R. K. and Hahnen, E. (2016). Compelling evidence for FANCM as a breast cancer susceptibility gene. Oncol. Res. Treat., 39. S. 54 - 55. BASEL: KARGER. ISSN 2296-5262
Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P. A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Mueller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R. K., Hahnen, E. and Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V. and Loibl, S. (2022). Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Ann. Oncol., 33. S. S166 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Rhiem, K., Bick, U., Kast, K., Niederacher, D., Solbach, C., Emons, G., Witzel, I., Brigitte, S., Bartram, C., Maass, N., Lemke, J., Kiechle, M., Mahner, S., Wieacker, P., Ortmann, O., Riess, O., Janni, W., Haaf, T. and Schmutzler, R. K. (2018). New structures of the German Consortium for Hereditary Breast and Ovarian Cancer. Oncol. Res. Treat., 41. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262
Rhiem, K., Herold, N., Bongartz, R., Schellong, G. and Schmutzler, R. (2014). Breast Cancer in young women after radiation therapy of Hodgkin disease in childhood and adolescence - individual therapeutic strategies. Oncol. Res. Treat., 37. S. 21 - 22. BASEL: KARGER. ISSN 2296-5262
Rhiem, K., Richters, L., Hahnen, E., Lampe, B., Rezai, M., Goehring, U. -J., Schumacher, C., Kuemmel, S., Ataseven, B. and Schmutzler, R. (2016). Benchmarking of the DKG check list for inclusion criteria of BRCA testing. Oncol. Res. Treat., 39. S. 59 - 60. BASEL: KARGER. ISSN 2296-5262
Rhiem, K. and Schmutzler, R. K. (2018). Comprehensive care for families with hereditary breast and ovarian cancer. Gynakologe, 51 (5). S. 403 - 409. CHAM: SPRINGER INTERNATIONAL PUBLISHING AG. ISSN 1433-0393
Rhiem, K. and Schmutzler, R. K. (2015). Risk factors and prevention of breast cancer. Onkologe, 21 (3). S. 202 - 211. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Rhiem, K. and Schmutzler, R. K. (2015). Risk factors and prevention of breast cancer. Onkologe, 21 (3). S. 202 - 211. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415
Rhiem, K. and Schmutzler, R. K. (2014). Risk-adapted surveillance. Focus on familial breast and ovarian cancer. Bundesgesundheitsblatt-Gesund., 57 (3). S. 307 - 312. NEW YORK: SPRINGER. ISSN 1437-1588
Rhiem, K., Schott, S., Tio, J., Speiser, D., Briest, S., Vesper, A. -S., Kast, K., Kiechle, M., Wockel, A., Mundhenke, C., Ditsch, N., Janni, W., Seitz, S. and Schmutzler, R. K. (2018). Results of intensified breast cancer Screening in women after Radiation for Hodgkin's lymphoma in childhood and adolescence. Oncol. Res. Treat., 41. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262
Rhiem, K., Wesselmann, S., Mensah, J., Bick, U., Blohmer, J. -U., du Bois, A., Emons, G., Gaissmaier, W., Hahne, A., Koch, K., Meindl, A., Scharl, A. J., Brigitte, S. and Schmutzler, R. K. (2018). Education Program of the German Consortium for Hereditary Breast and Ovarian Cancer and the German Cancer Sociey to improve genetic literacy and trans-sectoral cooperation in the Genome era. Oncol. Res. Treat., 41. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262
Richters, L., Rhiem, K., Wappenschmidt, B., Kiechle, M. and Schmutzler, R. (2014). Pathological complete response rates in patients with BRCA1/2-associated breast cancer after neoadjuvant chemotherapy. Oncol. Res. Treat., 37. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262
Staniczok, C., Ataseven, B., Heitz, F., Harter, P., Rhiem, K., Pauly, N., Traut, A. and Moubarak, M. (2022). Prevalence and clinical characterization of concurrent multiple deleterious germline mutations in German patients with epithelial ovarian cancer. Geburtshilfe Frauenheilkd., 82 (10). S. E165 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G. and Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann. Oncol., 29. S. 60 - 61. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Waha, A., Versmold, B., Kast, K., Kiechle, M., Ditsch, N., Meindl, A., Niederacher, D., Hahnen, E., Arnold, N., Mundhenke, C., Horvath, J., Bernd, A., Dikow, N., Hauke, J., Wappenschmidt, B., Riess, O., Schott, S., Speiser, D., Faust, U., Sutter, C., Rhiem, K. and Schmutzler, R. K. (2018). Consensus recommendation of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) on the transfer of multigene analysis data into the clinical care program. Oncol. Res. Treat., 41. S. 182 - 183. BASEL: KARGER. ISSN 2296-5262
Wassermann, K., Rhiem, K. and Schmutzler, R. (2014). Psychosocial Factors Relating to the Decision Against or in Favour for Prophylactic Surgery. Oncol. Res. Treat., 37. S. 111 - 112. BASEL: KARGER. ISSN 2296-5262